Every 10-Q that BioAge Labs, Inc. (BIOA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BIOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIOA filings page.
BioAge Labs is a clinical-stage biopharmaceutical company focused on cardiometabolic diseases driven by aging biology. For the three months ended June 30, 2026, it generated $2.5 million in collaboration revenue and reported a net loss of $26.1 million, or $0.58 per share. For the first six months of 2026, collaboration revenue was $5.2 million and the net loss was $48.4 million.
Research and development expenses for the six-month period rose to $44.8 million, driven mainly by lead candidate BGE-102, including completion of a Phase 1 trial, initiation of the QUELL-CV Phase 2 study and preparations for the QUELL-DME ophthalmology trial. General and administrative expenses were $15.2 million.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $381.3 million, with stockholders’ equity of $374.9 million and no term loan debt outstanding. Management states this capital is expected to fund operations and capital expenditures through 2029 while advancing BGE-102, APJ obesity programs and collaborations with Novartis and Eli Lilly.
BioAge Labs (BIOA) reported Q3 results showing initial collaboration revenue and strong liquidity as it advances metabolic disease programs. Collaboration revenue was $2.1 million in the quarter and $5.9 million year‑to‑date, driven by its Novartis agreement. Operating expenses were $25.2 million, leading to a net loss of $20.2 million and net loss per share of $0.56.
BioAge ended the quarter with $215.6 million in cash and cash equivalents and $295.6 million in total cash, cash equivalents, and marketable securities, and stated this is sufficient to fund planned operations at least one year after issuance of the statements. Deferred revenue was $8.1 million, reflecting ongoing work under the Novartis collaboration.
Subsequent to quarter‑end, the company filed a shelf registration permitting offerings of up to $250.0 million and entered an at‑the‑market Sales Agreement with Leerink Partners for up to $75.0 million in common stock, with a commission rate of up to 3.0%. As of October 31, 2025, shares outstanding were 35,855,037.